Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MG
Metagenomi Therapeutics, Inc. Common Stock
MGX
Mkt Cap
$29.5M
Volume
158.87K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MG
MGX
MG
Metagenomi Therapeutics, Inc. Common Stock
MGX
News
·
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Mkt Cap
$29.6M
Volume
158.87K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Insider
Filings
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics announced that CEO Jian Irish will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. The company remains on track to submit an IND application in Q4 2026 for MGX-001, its lead hemophilia A treatment program utilizing proprietary CRISPR gene-editing technology.
GlobeNewswire Inc. · Sep 1, 2026
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Over 50 pharmaceutical companies are advancing 55+ pipeline hemophilia drugs across various clinical development stages. Key players including Novo Nordisk, Roche, Regeneron, and others are developing innovative therapies with mechanisms like FVIII mimetics, gene therapies, and factor replacement treatments. Recent developments include Novo Nordisk's FDA submission for denecimig and Metagenomi's progress toward clinical trials for gene-editing therapy MGX-001.
GlobeNewswire Inc. · May 5, 2026
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Therapeutics announced a publication in Nature Structural & Molecular Biology highlighting MG119-28, a compact CRISPR nuclease demonstrating superior editing efficiency compared to previous compact nucleases. The nuclease showed 64% knockdown of target protein in mice via single AAV injection, supporting the company's path toward clinically relevant genome editing systems deliverable via AAV for non-hepatic indications including neuromuscular diseases.
GlobeNewswire Inc. · Apr 16, 2026
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.
GlobeNewswire Inc. · May 14, 2025
Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi, a precision genetic medicines company, announced upcoming scientific presentations and provided updates on its gene editing technology and pipeline. The company highlighted positive results from a nonhuman primate study for its hemophilia A treatment and advancements in its CRISPR-associated transposase (CAST) systems.
GlobeNewswire Inc. · May 2, 2025
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
Totus Medicines, a company developing small molecule medicines using DNA-encoded covalent library technology and AI/ML, has appointed Simon Harnest as its new Chief Financial Officer. This appointment comes as the company prepares to advance its lead covalent PI3Kα inhibitor, TOS-358, following positive Phase 1 results.
GlobeNewswire Inc. · Jan 28, 2025
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Metagenomi presented updated preclinical data for its hemophilia A program, including durable Factor VIII activity levels in an ongoing nonhuman primate study and positive results for its lead development candidate MGX-001.
GlobeNewswire Inc. · Dec 10, 2024
היום הוא המועד לתביעה נגד MGX: רוזן, פירמת עורכי דין מהשורה הראשונה, מעודדת את משקיעי Metagenomi, Inc לקבל ייעוץ לפני התאריך החשוב היום 25 בנובמבר בתביעה ייצוגית בניירות ערך – MGX
Rosen Law Firm is encouraging Metagenomi, Inc. (MGX) investors to seek legal advice before the important November 25, 2024 deadline for a securities class action lawsuit. The lawsuit alleges that Metagenomi misled investors about its business relationship with Moderna during its IPO.
GlobeNewswire Inc. · Nov 25, 2024
תאריך היעד לתביעה נגד MGX ביום שני: רוזן, משרד עורכי דין מהשורה הראשונה, מעודד את המשקיעים ב- Metagenomi, Inc לקבל ייעוץ לפני תאריך יעד חשוב של 25 בנובמבר בתביעה ייצוגית בניירות ערך – MGX
Rosen Law Firm reminds Metagenomi, Inc. investors of the November 25, 2024 deadline to join a securities class action lawsuit against the company. The lawsuit alleges that Metagenomi misled investors about its business relationship with Moderna during its IPO.
GlobeNewswire Inc. · Nov 22, 2024
DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024
Berger Montague has filed a securities class action lawsuit against Metagenomi Inc. on behalf of investors who purchased the company's securities between February 6, 2024 and September 26, 2024. The lawsuit alleges that Metagenomi and its executives misled investors about the company's prospects, including its relationship with Moderna.
GlobeNewswire Inc. · Nov 22, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
MG
MGX
Metagenomi Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
MGX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any MGX yet.
Related Tickers
MR
MRNA
—
Earnings